Catalyst Pharmaceuticals Announces Third Quarter 2014

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Catalyst Pharmaceuticals Announces Third Quarter 2014 Financial Results

CORAL GABLES, Fla., Nov. 14, 2014 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Catalyst Pharmaceuticals) (Nasdaq: CPRX ), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today reported financial results for the third quarter and nine months ended September 30, 2014.

"With the announcement of the positive results from our pivotal Phase 3 trial of Firdapse ™ in LEMS, the third quarter was truly transformative for Catalyst as it puts us on a pathway to initiate our NDA filing next year," said Patrick J. McEnany, Chairman and Chief Executive Officer of Catalyst. "We are committed to the LEMS patient community, currently suffering with this debilitating disease, and will be launching our expanded access program shortly. With our recent Industry Forum at the AANEM conference, we've seen enthusiastic support from the physician KOL's, as we continue to expand our pre-commercial activities, raising awareness of LEMS and Firdapse ™ ."

Recent Highlights

  • Positive top-line phase 3 data from Firdapse ™ in patients with Lambert-Eaton Myasthenic Syndrome (LEMS)
  • Presentation of top-line safety and efficacy results from the Phase 3 Firdapse ™ trial at the 139 th Annual Meeting of the American Neurological Association
  • Held an Industry Forum at the 61 st Annual Meeting of the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM)
  • Initiation of Phase 1b safety and tolerance study for CPP-115, a novel GABA aminotransferase (GABA-AT) inhibitor
  • Appointment of David D. Muth to EVP, Corporate Development
  • Appointment of David J. Caponera as VP Patient Advocacy and Reimbursement

Upcoming Milestones

  • Launch of Firdapse ™ expanded access program in November 2014
  • Top-line results from Tourette's Disorder Phase I/II investigator sponsored study
  • Initiate Firdapse ™ rolling NDA Submission
  • Exploration of additional indications for Firdapse ™ including Congenital Myasthenic Syndrome and downbeat nystagmus.

Financial Results

For the quarter ended September 30, 2014, Catalyst reported a GAAP net loss of $5,009,892, or $0.07 per basic and diluted share, compared to a GAAP net loss of $5,912,059, or $0.13 per basic and diluted share, for the same period in 2013. Excluding non-cash expense of $906,787 attributable to the change in fair value of liability-classified warrants, Non-GAAP 1 net loss was $4,103,105 or $0.06 per share for the third quarter of 2014. In comparison, Non-GAAP 1 net loss for the third quarter of 2013 was $3,235,458, or $0.07 per share, which excludes non-cash expense of $2,676,601 attributable to the change in fair value of liability-classified warrants.

For the nine months ended September 30, 2014, Catalyst reported a GAAP net loss of $12,019,031, or $0.19 per basic and diluted share, compared to a GAAP net loss of $10,799,938, or $0.25 per basic and diluted share, for the same period in 2013. Excluding non-cash expense of $1,465,892 attributable to the change in fair value of liability-classified warrants, Non-GAAP 1 net loss was $10,553,139 or $0.17 per share for the nine months ended September 30, 2014. In comparison, Non-GAAP 1 net loss for the nine months ended September 30, 2013 was $7,579,424, or $0.18 per share, which excludes non-cash expense of $3,220,514 attributable to the change in fair value of liability-classified warrants.

Research and development expenses for the third quarter of 2014 were $2,885,892, compared to $2,804,352 in the third quarter of 2013. For the nine months ended September 30, 2014, research and development expenses were $7,733,533, compared to $6,028,691 in the comparable period of 2013. Research and development expenses for the nine months ended September 30, 2014 increased when compared to the same period in 2013 as Catalyst continued its ongoing Phase 3 trial evaluating Firdapse™ for the treatment of LEMS and its other clinical trials and studies of Firdapse™. Catalyst expects that research and development expenses will continue to be substantial during 2014 as a result of ongoing development projects for both Firdapse™ and CPP-115.

General and administrative expenses for the third quarter of 2014 totaled $1,223,137, compared to $441,424 in the third quarter of 2013. For the nine months ended September 30, 2014, general and administrative expenses totaled $2,874,034, compared to $1,576,044 in the same period in 2013. The increase in general and administrative expenses is primarily due to an increase in non-cash stock based compensation due to timing of option awards, and consulting and marketing fees incurred in connection with the early stages of pre-commercial activities for Firdapse™.

As a development-stage biopharmaceutical company, Catalyst had no revenues in either the third quarter of 2014 or the first nine months of 2014.

At September 30, 2014, Catalyst had cash and cash equivalents, certificates of deposit and short-term investments of $41.4 million and no debt. Catalyst believes that its existing resources will be sufficient to support its currently anticipated operations through 2015.

Upcoming Investor Conferences

Catalyst's CEO, Patrick J. McEnany and COO/CSO, Dr. Steven Miller, will present at the following upcoming investor conferences:

  • Piper Jaffray 26 th Annual Healthcare Conference, December 2-3, 2014 at The Palace Hotel in New York City.
  • The Trout Group Annual 1x1 Management Access, January 12-15 in San Francisco, CA

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, including Lambert-Eaton Myasthenic Syndrome (LEMS), infantile spasms, and Tourette Syndrome. Catalyst's lead candidate, Firdapse™ for the treatment of LEMS, is currently undergoing testing in a global, multi-center, pivotal Phase 3 trial and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA). Firdapse™ is the first and only European approved drug for symptomatic treatment in adults with LEMS.

Catalyst is also developing a potentially safer and more potent vigabatrin analog (designated CPP-115) to treat infantile spasms, and epilepsy, as well as other neurological conditions associated with reduced GABAergic signaling, like post-traumatic stress disorder and Tourette Syndrome. CPP-115 has been granted U.S. orphan drug designation for the treatment of infantile spasms by the FDA and has been granted E.U. orphan medicinal product designation for the treatment of West Syndrome by the European Commission.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including whether the receipt of breakthrough therapy designation for Firdapse™ will expedite the development and review of Firdapse™ by the FDA or the likelihood that the product will be found to be safe and effective, whether an NDA for Firdapse™ will ever be accepted for filing by the FDA, the timing of any such NDA filing or acceptance, whether Catalyst will be the first company to receive approval for amifampridine (3,4-DAP), giving it 7-year marketing exclusivity for its product, whether any of Catalyst's product candidates will ever be approved for commercialization or successfully commercialized, and those other factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2013 and its other filings with the U.S. Securities and Exchange Commission (SEC), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.

_____________________________

1 Statements made in this press release include a non-GAAP financial measure. Such information is provided as additional information and not as an alternative to Catalyst's financial statements presented in accordance with U.S generally accepted accounting principles (GAAP). This non-GAAP financial measure is intended to enhance an overall understanding of Catalyst's current financial performance. Catalyst believes that the non-GAAP financial measure presented in this press release provides investors and prospective investors with an alternative method for assessing Catalyst's operating results in a manner that Catalyst believes is focused on the performance of ongoing operations and provides a more consistent basis for comparison between periods. The non-GAAP financial measure in this press release excludes from the calculation of net loss the expense (or the income) associated with the change in fair value of the liability-classified warrants. Non-GAAP net loss per share is calculated by dividing non-GAAP net loss by the weighted average common shares outstanding.

CATALYST PHARMACEUTICAL PARTNERS, INC.
CONDENSED STATEMENTS OF OPERATIONS (unaudited)
     
  For the Three Months
 Ended September 30,
For the Nine Months
Ended September 30,
  2014 2013 2014 2013
         
Operating costs and expenses:        
Research and development $ 2,885,892 $ 2,804,352 $ 7,733,533 $ 6,028,691
General and administrative  1,223,137  441,424  2,874,034  1,576,044
Total operating costs and expenses.  4,109,029  3,245,776  10,607,567  7,604,735
Loss from operations (4,109,029)  (3,245,776) (10,607,567) (7,604,735)
Interest income  5,924  10,318  54,428  25,311
Change in fair value of warrants liability (906,787) (2,676,601) (1,465,892) (3,220,514)
Loss before income taxes  (5,009,892)  (5,912,059) (12,019,031) (10,799,938)
Provision for income taxes  --  --  --  --
Net loss $ (5,009,892) $ (5,912,059) $(12,019,031) $ (10,799,938)
Net loss per share – basic and diluted $ (0.07) $ (0.13) $ (0.19) $ (0.25)
Weighted average shares outstanding – basic and diluted 67,169,383 44,686,310 62,539,571  42,529,432
 
CATALYST PHARMACEUTICAL PARTNERS, INC.
CONDENSED BALANCE SHEETS
 
   
September 30, 
2014
 
December 31,
2013
  (unaudited)  
ASSETS    
Current Assets:    
Cash and cash equivalents $ 11,263,677 $ 2,215,958
Certificates of deposit 3,714,634 4,011,576
Short-term investments  26,468,664 17,483,062
Prepaid expenses and other current assets 4,317,358 1,609,442
Total current assets 45,764,333 25,320,038
Property and equipment, net 71,280 40,628
Deposits 8,888  8,888 
Total assets $ 45,844,501 $ 25,369,554
     
LIABILITIES AND STOCKHOLDERS' EQUITY    
Current Liabilities:    
Accounts payable $ 524,795 $ 850,789
Accrued expenses and other liabilities 5,414,301 1,288,820
Total current liabilities  5,939,096 2,139,609
Accrued expenses and other liabilities, non-current 15,770 19,131
Warrants liability, at fair value  3,266,917 1,819,562
Total liabilities 9,221,783 3,978,302
     
Total stockholders' equity 36,622,718 21,391,252
Total liabilities and stockholders' equity $ 45,844,501 $ 25,369,554

Investor Contact Brian Korb The Trout Group LLC (646) 378-2923 Media Contacts David Schull Matt Middleman, M.D. Russo Partners (212) 845-4271 (212) 845-4272 Company Contact Patrick J. McEnany Catalyst Pharmaceuticals Chief Executive Officer (305) 529-2522

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Telit Cinterion Tests Its Defense Connectivity Pitch

Updated Category News Views 107

Defense connectivity is a messy business, and Telit Cinterion is leaning straight into the mess at NATO Edge 2026 in Izmir, Turkey. From November 17 through 19, the company is using Booth L86 to show how several wireless links can live inside one mission-focused setup. That may sound like standard trade-show wallpaper, but the underlying problem is very real: military and...

Continue Reading
Hyster-Yale's $125 Million Convertible Debt Shuffle

Updated Category News Views 86

Forklifts do not make headlines often, but debt terms sure can. Hyster-Yale has proposed a $125 million private offering of convertible senior notes due November 15, 2031, with buyers able to take another $18.75 million if the initial purchasers exercise their option. For NYSE:HY holders, this is not a victory lap or a distress flare by itself. It is a refinancing...

Continue Reading
Innoviz's 1-for-20 Split Is a Listing Lifeline Test

Updated Category News Views 45

A twenty-share pile of INVZ is about to become one share, and nobody should confuse that paperwork with a turnaround. Innoviz plans to enact a 1-for-20 reverse split at 11:59 p.m. Eastern on Friday, December 4, with split-adjusted trading expected when Nasdaq opens on December 7. This is a blunt instrument aimed at one immediate problem: getting the quoted share price...

Continue Reading
Sectra's RSNA AI Pitch Centers on Workflow, Not Hype

Updated Category News Views 121

Radiology has heard enough grand AI promises to fill a hospital basement, which makes Sectra's RSNA 2026 message refreshingly grounded. The Swedish imaging IT and cybersecurity company is putting its weight behind the unglamorous part of adoption: fitting AI into the daily diagnostic machinery without handing clinicians another awkward system to babysit. That is where...

Continue Reading
Sysco's Northern California Labor Deal Gets Bigger

Updated Category News Views 20

One hundred forty-four drivers may not rattle a giant food distributor by themselves, but labor agreements have a habit of growing legs. Sysco's Northern California and Nevada regional contract has added members from Teamsters Locals 386 and 431, bringing its coverage above 1,100 workers. For investors watching Sysco, this is less about one afternoon's headline and more...

Continue Reading
Oracle Takes AI to Construction's Messy Project Middle

Updated Category News Views 164

A stalled drywall inspection can wreck a schedule faster than any glossy AI pitch can repair it. That is the grimy, practical corner Oracle is aiming at with its latest Oracle Primavera Cloud upgrades: the daily hunt for answers, the repeated logging of familiar risks, and the finger-pointing that starts when a milestone is suddenly in danger. This is not a chatbot being...

Continue Reading
Cadence Marks $2.7 Million for St. Jude Family Care

Updated Category News Views 112

Small Wheels, Serious Purpose Tiny tricycles, flour-dusted bake-sale tables, and family pledges have pushed Cadence Education’s St. Jude partnership to $2.7 million since 2018. That number is not a flashy balance-sheet item, nor should anybody try to dress it up as one. It is the accumulated result of school communities showing up year after year, and in a sector built...

Continue Reading
Elijah Craig Uses AI Toasts to Sell a Warmer Pour

Updated Category News Views 38

A Speech Prompt With a Bourbon Label Few things expose holiday nerves faster than a raised glass and a room waiting for somebody to say something memorable. Elijah Craig has decided that awkward little moment is marketing territory, rolling out its Digital Perfect Pour, Perfect Toast Generator for mobile and desktop users ahead of the holiday season. The tool asks for a...

Continue Reading
TORM Rejects Hafnia's No-Premium Merger Pitch Again

Updated Category News Views 112

A 19.8% shareholder heading for the exit can rattle a shipping stock before breakfast, and TORM has answered the noise with a flat refusal to pretend Hafnia's merger approach was good enough. The message from Hellerup on November 18 is unusually blunt: Hafnia made several conditional, all-share proposals, TORM saw no effective premium for control, and the board rejected...

Continue Reading
Gozney Brings in Armin Boehm for a Global Growth Push

Updated Category News Views 95

A pizza oven company has just made a very grown-up management move. Gozney appointed Armin Boehm as Global President, effective from October 31, putting an experienced consumer-brand operator beside founder, designer and CEO Tom Gozney at a moment when the business says it is becoming a global omnichannel operation. This is not the sort of announcement that comes with...

Continue Reading

Top 5 Most Recently Viewed Articles

Shell PLC's Strategic Share Repurchase Program Explained

Updated Category News Views 198

Understanding Shell PLC's Share Repurchase Strategy Shell plc has recently made headlines with its ongoing share buyback program. On a notable date, the company announced a significant purchase of its own shares intended for cancellation. This action is a part of its broader strategy to enhance shareholder value and optimize its capital structure. Details of the Share...

Continue Reading
Teck Resources Faces Maintenance Challenges at Chile Operations

Updated Category News Views 255

Maintenance Updates from Teck Resources Limited Teck Resources Limited (TSX: TECK.A and TECK.B, NYSE: TECK) has recently reported important updates regarding maintenance challenges at its operations in Chile. A mechanical issue has emerged at the Carmen de Andacollo (CdA) site, necessitating a temporary shutdown of the SAG mill. According to the latest information,...

Continue Reading
Neinor Homes Achieves FY24 Targets and New Shareholder Returns

Updated Category News Views 151

Neinor Homes Achieves Fiscal Targets for 2024 In a recent update, Neinor Homes reports successful fulfillment of its Adjusted Net Income target of €65 million for fiscal year 2024. The company, known for its prominence in residential property development, is now poised for continued growth. With the expected announcement of its fiscal results set for the latter part of...

Continue Reading
STG Logistics Staff Earn Supply Chain Accolades

Updated Category News Views 41

There's a fresh breeze running through the corridors of STG Logistics. Why? Because two of their own have snagged some serious recognition with the 2026 Women in Supply Chain Awards. This isn't just another blip on the corporate radar—it's a salute to the powerhouse of leadership and innovation nestled within the company's ranks. Geoff Anderman, the CEO himself, was...

Continue Reading
WISeKey International Holding Ltd Unveils AGM Agenda for Stakeholders

Updated Category News Views 284

WISeKey International Holding Ltd Unveils AGM Agenda for Stakeholders WISeKey International Holding Ltd, recognized for its significant contributions in the fields of cybersecurity and IoT, has announced the essential items for consideration by its shareholders at the upcoming Annual General Meeting (AGM). This important gathering, set to foster engagement between...

Continue Reading